Resultados de procura - Pascale Fouqueray

  • Mostrando 1 - 13 Resultados de 13
Limitar resultados
  1. 1
    Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial

    Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial por Julie Dubourg, Kohjiro Ueki, Jean‐Marie Grouin, Pascale Fouqueray

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes

    Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes por Giovanni Pacini, Andrea Mari, Pascale Fouqueray, Sébastien Bolze, Michael Roden

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

    Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes por Pascale Fouqueray, Xavier Leverve, Éric Fontaine, Mathurin Baquié, Claes B. Wollheim

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

    Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Mul... por Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean‐Marie Grouin, Kohjiro Ueki

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 2): A 52‐week, open‐label, multicentre phase 3 trial

    Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 2): A 52‐w... por Julie Dubourg, Pascale Fouqueray, Damien Quinslot, Jean‐Marie Grouin, Kohei Kaku

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

    Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action por Sophie Hallakou‐Bozec, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, David E. Moller

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period

    Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 3): A randomized, double‐blind, placebo‐controlled phase... por Caroline Reilhac, Julie Dubourg, Carole Thang, Jean‐Marie Grouin, Pascale Fouqueray, Hirotaka Watada

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy por Pascale Fouqueray, Valdis Pīrāgs, Silvio E. Inzucchi, Clifford J. Bailey, Guntram Schernthaner, Michaëla Diamant, Harold E. Lebovitz

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy

    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy por Pascale Fouqueray, Valdis Pīrāgs, Michaëla Diamant, Guntram Schernthaner, Harold E. Lebovitz, Silvio E. Inzucchi, Clifford J. Bailey

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration

    Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration por Dominique Détaille, Guillaume Vial, Anne‐Laure Borel, Cécile Cottet-Rouselle, Sophie Hallakou‐Bozec, Sébastien Bolze, Pascale Fouqueray, Éric Fontaine

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

    Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes por Sophie Hallakou‐Bozec, Guillaume Vial, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, Anne‐Laure Borel, Éric Fontaine, David E. Moller

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  12. 12
    Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents

    Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents por Rachel J. Perry, Rebecca Cardone, Max C. Petersen, Dongyan Zhang, Pascale Fouqueray, Sophie Hallakou‐Bozec, Sébastien Bolze, Gerald I. Shulman, Kitt Falk Petersen, Richard G. Kibbey

    Publicado 2016
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

    Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity por Vincent Jacques, Sébastien Bolze, Sophie Hallakou‐Bozec, Anthony W. Czarnik, Ajit S. Divakaruni, Pascale Fouqueray, Anne N. Murphy, Lex H.T. Van der Ploeg, Sheila H. DeWitt

    Publicado 2021
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: